Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Review ArticleReviews

Integrated Treatment of Breast Cancer-related Lymphedema: A Descriptive Review of the State of the Art

PAOLO MARCHICA, SALVATORE D’ARPA, STEFANO MAGNO, CRISTINA ROSSI, LUANA FORCINA, VITA CAPIZZI, SEBASTIANO OIENI, CARMELA AMATO, DARIO PIAZZA and VITTORIO GEBBIA
Anticancer Research July 2021, 41 (7) 3233-3246; DOI: https://doi.org/10.21873/anticanres.15109
PAOLO MARCHICA
1Plastic Surgery Unit, University of Padua, Padua, Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SALVATORE D’ARPA
2Plastic Surgery and Breast Unit, La Maddalena Clinic for Cancer, Palermo, Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
STEFANO MAGNO
3Center for Integrative Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CRISTINA ROSSI
3Center for Integrative Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
LUANA FORCINA
3Center for Integrative Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
VITA CAPIZZI
2Plastic Surgery and Breast Unit, La Maddalena Clinic for Cancer, Palermo, Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SEBASTIANO OIENI
2Plastic Surgery and Breast Unit, La Maddalena Clinic for Cancer, Palermo, Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CARMELA AMATO
4Serena a Palermo Association, Palermo, Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DARIO PIAZZA
5GSTU Foundation for Cancer Research, Palermo, Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
VITTORIO GEBBIA
5GSTU Foundation for Cancer Research, Palermo, Italy;
6Integrative Medicine in Oncology Program, Medical Oncology Unit, La Maddalena Clinic for Cancer, Palermo, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: vittorio.gebbia@gmail.com
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background/Aim: Upper limb breast cancer-related lymphedema (BCRL) is a chronic and severe condition affecting a significant percentage of breast cancer survivors. Even though its physiopathology is well-known, there is no worldwide consensus on BCRL evaluation and a gold-standard treatment. This narrative review aims at providing a brief descriptive overview with regard to BCRL treatment modalities. Materials and Methods: We conducted a literature search within the PubMed database, and 33 articles out of 56 were selected, including reviews, systematic reviews, and meta-analyses aiming find the most updated evidence regarding BCRL treatment modalities. Results: Physical exercise (aerobic exercise, resistance exercise, aquatic therapy), bandages, and intermittent pneumatic compression were shown to be most effective in BCRL patients, in terms of swelling reduction in the acute-intensive phase. Furthermore, physical exercise was beneficial also as a maintenance tool. Manual lymphatic drainage demonstrated efficacy in preventing secondary lymphedema if applied immediately after breast cancer surgery or in early phases of BCRL or as a maintenance tool. Complementary procedures such as acupuncture, reflexology, yoga and photo-biomodulation therapy did not show conclusive results in BCRL treatment. Surgery was shown effective in managing symptoms (liposuction), preventing (lymphaticovenular anastomosis) and treating BCRL (vascularized lymph node transfer). Conclusion: BCRL is still a challenging condition either for breast cancer survivors and clinicians, deeply impacting patient functioning and quality of life. Due to the lack of globally accepted criteria in evaluating BCRL, to date a gold standard treatment for this widespread issue is still needed.

Key Words:
  • Breast cancer-related lymphedema
  • physical therapy
  • physical exercise
  • surgery
  • photo-biomodulation therapy
  • complementary medicine
  • review

Improved survival rates in breast cancer patients contribute to an increased number of survivors complaining of upper limb Breast Cancer-Related Lymphedema (BCRL), which is a secondary lymphedema after surgery and radiation therapy (1). BCRL is a common complication occurring after lymph node dissection for breast or upper limb tumors (e.g., melanoma), and it is generally caused by an excessive accumulation of protein-rich fluid (lymph) in tissue extracellular spaces that causes transient or persistent soft tissue swelling (2). Up to 30% (3-5) of breast cancer survivors, may suffer from BCRL and its physical and psychological consequences such as: pain, pitting edema, upper limb heaviness and discomfort, decreased range of motion of the affected joints, recurrent skin infections and ulcers, elephantiasis, cutaneous angiosarcoma, depression, anxiety, body image-related disorder. Quality of life (QoL) is dramatically worsened by BCRL.

Lymphedema (LYE) might be defined as “an increase of more than 10% in volume between the abnormal and normal arm” or “a difference of more than 200 ml in arm volume or more than 20 mm in the circumference between the abnormal and normal arm” (6). All variants of LYE stem from an imbalance between production and drainage of protein-rich fluid, i.e., lymph. Secondary LYE is a consequence of a primary condition that does not directly impair lymphatic function and is the most frequently occurring condition. Primary LYE may be caused by a congenital dysfunction or anomaly of the lymphatic system, and it may be sporadic or hereditary or syndrome-associated and is less common (7, 8) than secondary LYE (9).

Secondary LYE finds its roots in obstruction or disruption of the lymphatic system due to cancer, radiation therapy, chronic venous insufficiency, surgery, trauma, or infections. Wuchereria bancrofti, responsible for filariasis, is the most common cause of secondary LYE worldwide (10).

Some risk factors participate in developing secondary LYE, such as obesity and pathological BMI, chemotherapy, the number of lymph nodes removed (1, 11, 12). Some authors advocated physical exercise, but this theory has been rejected, as discussed below (13, 14). However, predisposing factors have not been yet identified. Despite older literature claiming the healthy state of the unaffected side, recent studies advocate the existence of differences between the arms’ drainage function in the absence of any cancer or surgical treatment. More specifically, an unaffected lymph node side that non dissected may not be considered “normal” and presenting a slower tracer appearance time. Such differences in lymphatic function between the two limbs may predispose to LYE development (15).

International Society of Lymphology (ISL) classified the limb LYE in 4 stages: stage 0 to indicate subclinical or latent limb LYE with no evident volume gain and swelling but an initially impaired lymphatic network; stage I to indicate mild LYE with visible transient limb swelling and volume gain but with the possibility to be reduced with limb elevation; stage II to indicate non-reducible LYE with poor pitting edema and little to no response with limb elevation, as an indicator of tissue changes; stage III to indicate overt LYE with tissue changes such as fat and tissue fibrosis, hypertrophic thickened skin and limb deformities up to lymphostatic elephantiasis with absent pitting of edema (16).

Diagnosis of LYE is made by physical examination and is aided by linear circumference measurements or volumetric arm measurements based on water displacement. Advanced staging tools are indocyanine green lymphography, US and MRI, lymphoscintigraphy, lymphography, LASER scanning, bioimpedance spectroscopy (L-Dex score or lymphoedema index), perometry and tonometry (17).

Early detection and treatment on BCRL may reduce chronic BCRL rates by >50% (18, 19). Together with the increase of BCRL, the need for treatment is rising. However, BCRL is considered a chronic disease, and its management aims at disease control, prevention of complications and limb function preservation (20). Some medical and surgical solutions have been proposed, including physical exercise and treatment related to Complete (or Complex) Decongestive Therapy (CDT), medical treatment, surgery, complementary and integrative therapies. Here we present a review of literature regarding the state of the art of BCRL treatment in the last five years, with a brief discussion for each modality and its effectiveness in BCRL management.

Materials and Methods

This review aims at analyzing and discussing current knowledge on BCRL based on the last five years-literature. The review was conducted by search within the PubMed database. The authors (PM and SD) independently searched the past studies in the last five years using the following medical subject heading (MeSH) terms and free text words: “breast” AND “cancer” AND “lymphedema” AND “treatment.” The following filters were applied: “Clinical Trial”, “Meta-Analysis”, “Randomized Controlled Trial”, “Review”, “Systematic Review”, “in the last 5 years”, “English”, “Systematic Reviews”, “MEDLINE”. Our initial search yielded 56 studies, 23 of which were deemed not to be relevant after screening the titles and the abstract content because they dealt with other topics than BCRL treatment. Afterward, the reviewers screened the full text of the remaining 33 studies and extracted the recommendations that emerged from these papers. The authors discussed any discrepancies before including the conclusive evidence in this paper. Single case-reports and case-series and single RCT were not considered.

Results

The authors displayed 56 articles after the research. Among them, only 33 papers were found relevant to the BCRL treatment topic, as shown in Table I. Manual Lymphatic Drainage (MLD) was discussed in 7 reports, bandage and garments roles were investigated in 2 different papers. Only one paper discussed Kinesio taping and intermittent pneumatic compression. Five articles from Eastern authors described the role of acupuncture. Most articles focused on physical exercise (14 papers on 23), evidencing the prominent and widespread part of physical activity in the treatment of BCRL. Surgical treatment of BCRL was discussed in only four scientific works, suggesting that surgery is not universally considered as a first-choice option in the treatment of BCRL yet. Four articles investigated the role of the emerging photo-biomodulation therapy. Finally, five articles discussed the role of complementary alternative medicine (yoga, reflexology).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table I.

Articles found relevant to BCRL treatment.

Twenty-three articles (Table II) were not relevant to the aim of this work as they concerned topics other than the treatment of BCRL, such as epidemiology, comorbidities and impact of BCRL, diagnostic studies, the effect of radiotherapy and chemotherapy on LYE onset, diagnostic and therapeutic surgical procedures causing LYE, the safety of hand surgery following prior breast cancer treatment, air travel safety in breast cancer patients, and generic physical activity recommendation in people with cancer. Papers defined by the authors as of major scientific importance according to the topics covered are outlined in Table III.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table II.

Studies not relevant to BCRL treatment.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table III.

Most relevant studies on BCRL treatment according to the Authors’ opinion.

Discussion

Breast cancer represents the most common cancer among women, with 65.5 cases per 100,000 women (21, 22). BCRL represents a social plague and a stigma of cancer. Its treatment is, therefore, crucial in the physical and psychological rehabilitation of women to enhance QoL. Nevertheless, no globally accepted guidelines exist regarding BCRL treatment because of the insufficient level of evidence reached by most published papers due to small sample sizes, heterogeneity of patients and treatments provided, and treatment adherence. A brief discussion regarding the state of the art of BCRL is presented below, taking into consideration every kind of therapy discussed and investigated in the last five years’ systematic reviews and meta-analyses. Physical, surgical, medical, and complementary therapies used in BCRL treatment are described below.

Physical therapy. Physical therapy includes the four pillars of Complete or Complex Decongestive Therapy (CDT): manual lymphatic drainage, bandaging and garments, physical exercise, and skincare practice. CTD is considered the first line and the most widely accepted treatment for patients affected by BCRL (20). However, CDT is characterized by a complexity of protocols, thus needing long treatment duration and expensive costs that often discourage patients. CDT internationally accepted best practice includes a first phase characterized by an intensive treatment able to decongest the arm through compression bandaging and manual lymph drainage and a second maintenance phase. The patient becomes the main actor of his treatment by wearing compressive garments (23). The mainstays of CDT are listed and discussed below:

Manual lymphatic drainage (MLD) consists of specialized movements that act as a pump on the skin to improve lymph flow and reabsorption. As a result, it reduces the swelling and fibrosis in the affected limb. MLD may be conducted using the Vodder method (24) or Földi’s technique (25). It enhances muscle tissue elasticity and beneficially acts on autonomous nervous system activity, increasing parasympathetic tone.

MLD has a beneficial effect but cannot significantly reduce or prevent the risk of long-term LYE, although the literature is not univocal as regards its efficacy (6, 26) and its effect seems inconclusive as it reduces arm volume but does not improve subjective symptoms and arm function (27, 28). Its failure may be attributed to multiple risk factors and patient’s heterogeneity, which may influence outcomes. Nevertheless, some authors advocate its effectiveness in preventing secondary LYE when MLD is applied immediately after breast cancer surgery (29, 30), in early phases of BCRL (31), and even in BCRL-affected patients (32, 33), by reducing arm volume. However, it is not completely clear if MLD should be part of the therapy after breast cancer surgery and seems to be related to the severity of BCRL (27).

Bandaging and garments reduce fluid formation by means of compression producing counterpressure, reducing the subsequent swelling (29, 34). Standard sleeves have inconclusive effects in reducing arm volume compared to compression bandages or fitted sleeves, which showed beneficial volume reduction (27). Indeed, a standard sleeve is configured not as a treatment modality for the intensive phase of BCRL but as a maintenance tool for the leanest volume, reducing the risk for regaining volume or early stage after the onset BCRL (35). However, the standard sleeves may have a role in preventing additional swelling. Outcomes deriving from their use must be checked regularly (27). On the other hand, bandages have a role in the intensive phase, as they stimulate the resorption of the interstitial lymph fluid and have a more influential role in reducing volume compared to standard sleeves (35). However, the pressure generated by these devices should be carefully assessed by professional therapists.

Kinesio taping can be added to complete decongestive therapy because it generates a low pressure on the skin, improving lymphatic flow, by applying elastic tapes to the skin. Mechanoreceptors simulation and the elastic action seem to influence the lymphatic system (36, 37). A recent meta-analysis (38) discussed the role of Kinesio taping role in BCRL. Kinesio taping reduced upper limb volume but, compared to other treatments, no significant difference was evidenced. However, the studies investigated by Kasawara presented a low methodological quality and different forms of Kinesio taping application (38); thus, it does not allow to conclude the role of Kinesio taping in BCRL treatment.

Intermittent pneumatic compression (IPC) refers to a system composed of an air pump and inflatable auxiliary sleeves or gloves (boots when used for lower limbs) to improve venous and lymphatic circulation. Although IPC effectively reduces BCRL volume in the intensive phase, they cannot be considered a maintenance tool because they only stimulate the drainage in working collectors and do not actually seem to reduce interstitial protein-rich fluid resorption (35).

Physical exercise acts as a muscular pump promoting lymph flow and reducing soft tissue swelling (2). Its effectiveness is also proven in patients receiving adjuvant therapy, as it reduces upper limb volume and diameter and lowers the risk of BCRL (35, 39). Devoogdt et al. investigated the effect of exercise with or without MLD association, finding no difference among the groups (40).

One of the most frequent physical exercise obstacles is represented by compliance to programs and the lack of healthcare providers’ knowledge regarding training type and prescription.

A systematic metanalysis defined aerobic exercise as “any activity that uses large muscle groups, can be maintained continuously and is rhythmic in nature” (41), like cycling, dancing, hiking, jogging/long-distance running, swimming, and walking. It appeared feasible and safe and did not imply increasing BCRL symptoms or development. Furthermore, it has a beneficial effect in reducing upper limb volume (42), improving upper body strength and endurance, reducing body fat and waist and hip circumference, and increasing muscle mass, associated with psychological and emotional benefits (43).

Nordic walking (NW) defines an aerobic physical activity in which poles support walking; it is low-cost and easy to perform and, thus, it is a safe, attractive, and interesting physical exercise for patients affected by breast cancer sequelae (44). It has been demonstrated that NW provides positive changes in BCRL symptoms, reduces extracellular fluid, the circumference of the arm, and the LYE absolute and relative volumes (27, 35, 45). Furthermore, NW helps in women’s perception of BCRL regarding heaviness and tightness and upper limbs disability. However, the most significant difficulty in using NW in BCRL concerns the lack of knowledge of patients and therapists regarding the ground were to perform the exercise, the intensity, and the exercise duration. These concerns make the current studies of low methodological quality and make it challenging to extrapolate exact data regarding NW protocols. Thus, the importance of qualified instructors’ interfaces with the physician and the patient and a learning phase of performing NW before they perform it independently. A recent systematic review concluded that a safe prescription to perform NW in women with BCRL might be three times a week exercise, up to 1 hour per session, the intensity of 70-80% maximum heart rate, and 11-14 of perceived exertion scale (Borg rate) (45). Finally, no evidence exists regarding any adverse effect caused by NW (e.g., falls, commonly described in association with chemotherapy due to toxicity and osteoporosis). Therefore, NW may be considered a safe alternative in BCRL rehabilitation.

Resistance training programs performed on strength-training machines have been investigated with regards to their role in BCRL. In addition to determining an improvement in QoL, psychological, cognitive, and social condition, muscle strength, fatigue, pain, and aerobic capacity, resistance training are considered safe as it do not affect the development or worsening of LYE (33, 42, 46-48), if there is control and progression in training (49), as reported by previous literature (14). Hence, resistance exercise should be considered an additional treatment in cancer patient rehabilitation (48). Several authors depict the resistance exercise as beneficial for BCRL treatment due to its significant reduction (35, 42, 43, 50, 51) and increased upper and lower body muscular strength (27, 42, 52). Standardization of intensity training is difficult due to patient heterogeneity, differences in measurements used and patients’ compliance. Few patients report negative effects of resistance exercise. Thus, a resistance training program might be of benefit in BCRL treatment (50).

Aquatic therapy refers to a type of physical exercise that takes advantage of water properties. Aquatic therapy acts as activating muscle pump mechanism and, due to the hydrostatic pressure of water, improves lymphatic circulation. Moreover, it facilitates aerobic exercise, helps muscle strengthening due to the water’s natural resistance, and reduces the risk of musculoskeletal injuries while performing the exercise. Furthermore, warm water acts on the imbalance of the autonomous nervous system, increasing parasympathetic activity and decreasing sympathetic tone. A single meta-analysis has been found in literature describing the effect of aquatic therapy in BCRL. However, although no adverse events were reported, no significant benefits of aquatic therapy were evidenced, with no significant difference regarding LYE status and volumetric limb change and physical function of upper limb comparing aquatic therapy to conventional physical exercise and standard care for BCRL. Hence, patients should be addressed to the physical activity to which they can be more compliant (53).

Skincare has a role in preventing infection and subsequent complications (2).

Lymphedema surgery. LYE surgery is an expanding and (relatively) recently introduced tool. It is traditionally considered the last option in BCRL treatment when other measures have failed (54), although early treatment might reduce disease prevention. Indications include inadequate BCRL reduction and patient satisfaction after conservative medical or physical therapy, persistent pain, severely compromised limb function, recurrent lymphangitis, and patient accepting a more invasive treatment as surgery (55). Techniques are distinguished in reductive and reconstructive surgeries:

  • Reductive surgery

    • o. Liposuction is a reductive technique and aims at reducing the arm’s volume by removing the excess fibrotic and circumferentially hypertrophied fat tissue through a liposuction cannula (56). As conventional liposuction, postoperative treatment needs the use of life-long compressive garments to prevent a recurrence. Liposuction demonstrated efficacy in moderate-to-severe BCRL (31), but it does not improve lymphatic drainage and may be considered a symptomatic treatment. Surgical resection is an alternative.

  • Reconstructive surgery

    • o. Lymphaticovenular anastomosis (LVA) is a reconstructive method that aims at bypassing the obstruction to lymphatic outflow by creating a direct connection between the lymphatic vessels in the subcutaneous tissue and the veins upstream to the lymphnodes, to redirect the protein-rich fluid (lymph) to the venous circulation (57, 58). This way, the scarred and lymphnode deprived axylla is bypassed.

    • o. Lymphatic-lymphatic bypass grafts takes advantage of an intact and unaffected lymphatic vessel to bypass the obstructed area (59). Different dyes are used to detect lymphatic vessels before performing anastomosis and anastomosis patency checks, and follow-up may be conducted through lymphoscintigraphy (55). LVA demonstrated efficacy in advanced BCRL but might also be an effective tool in preventing or slowing down disease progression (31).

    • o. Vascularized lymph node transfer (VLNT) aims at reconstructing the resected lymph nodes and at re-connecting lymphatic channels (60). The donor lymph nodes site is often localized in the groin or abdomen, and the harvested nodes are inset into the armpit to replace the native ones. VLNT surgery seems to interrupt a life-long physical and conventional therapy and demonstrated efficacy in advanced BCRL (31).

A recent meta-analysis (2019) (61) compared the efficacy of surgery for prevention and treatment of BCRL by investigating the tissue volume and distribution, the limb composition, and by evaluating the BCRL status through the use of imaging exams (lymphoscintigraphy, lymphangiography, MRI, US, CT scan) (17, 62) after performing LVA (63, 64) and VLNT (65). Despite reporting low-certainty evidence in the effectiveness of LVA and VLNT respectively in preventing BCRL (63, 64) and treating stage II LYE (65), the meta-analyses showed that surgery provides encouraging results. Regarding LVA, it emerged that this technique determined a reduction in the incidence of BCRL compared to a non-operative treatment up to 24 months after surgery (63, 64). VLNT appeared to be effective in limb volume, pain, heaviness sensation reduction, and function score improvement. Indeed, the VLNT group presented a 57% reduction of mean limb volume than the control group that received the conventional treatment (18% limb volume reduction). Furthermore, pain, heaviness sensation reduction, and function score showed improvement after VLNT (65).

Limitations in the paper by Markkula et al. (61), consisted in the fact that none of the included studies discussed long-term complications (cellulitis, lymphangitis, lymphadenitis, skin ulcers, lymphorrea), and only the paper on VLNT by Dionyssiou et al. (65) reported a reduction with regards to short-term complication (seroma, lymphorrea, wound dehiscence, wound infection) in the VLNT group. Furthermore, only three studies were considered eligible for the review; thus, all results were based on a total of 131 patients. Hence, the small sample size does not allow to identify patients’ subgroups to identify factors that may be predictive of failure or success of surgical therapy. Finally, no other techniques have been included in the review, and no comparison was made between the effectiveness of a surgical procedure against another. Therefore, further studies are required to determine the efficacy of BCRL surgery as regards prevention and treatment. However, LVA and VLNT surgery are potentially able to decide on beneficial effects in BCRL affected patients.

A previous systematic review regarding VLNT surgery investigated 18 studies (309 limbs, of which 191 BCRL of the upper limbs) and showed that 91% had improvement in limb circumference, 86% had improvement in limb volume, and 60% had improvement of flow at lymphoscintigraphy/lymphangiography. No donor site persistent LYE was found (66). Hence, VLNT surgery was demonstrated to be a safe and effective tool for BCRL treatment.

Delayed breast reconstruction with autologous tissues deserves special consideration. Indeed, to date, it is unclear whether autologous reconstruction is useful for treating BCRL. A vascularized pedicled or free healthy tissue may provide relief from BCRL (67, 68), as discussed in the paper by Siotos. However, the benefit provided by the addition of VLNT to delayed breast reconstruction appears more effective than the microsurgical breast reconstruction alone. This finding may be explained by the flap acts’ nodal component, which acts as the largest contributing factor in BCRL improvement. Nonetheless, it has been demonstrated that a flap introduced into a LYE affected area serves as a trigger to the formation of new lymphatic vessels (68), because providing roots for lymph outflow. Finally, all the studies reviewed by Sotos agree that delayed breast reconstruction does not have a role in worsening BCRL (69).

Photobiomodulation therapy. Only a meta-analysis is available as regards photobiomodulation therapy (PBMT) (70). PBMT is a light therapy (wavelength 650-1000 nm), and it is a type of phototherapy deemed capable of improving lymphatic drainage, stimulating lymphangiogenesis, reducing inflammation and related pain (71), improving the wound healing process (72), and finally softening fibrotic tissue (thus its employ in the modulation of scarring process and improving lymphatic flow) (29). A previous systematic review recommended a dose of 1-2 J/cm2 per point to treat the fibrotic area and volume reduction effectiveness (27). Other authors compared PBMT to sham laser for limb volume and circumference reduction, pain relief and found a more effective action of the first (73). The most recent meta-analysis (70) included nine RCTs that investigated the effects of PBMT on BCRL, but the conflicting results did not allow to clarify the effectiveness of PBMT. Indeed, no statistically significant difference was found in arm circumference, arm volume, grip strength, and pain related to BCRL between the patients who received PBMT and the control groups receiving other treatments. Furthermore, the previous studies’ sample size was limited; thus, no significant effect of PBMT in the management of BCRL was found, and no consensus has been reached yet on the PBMT effect.

Medical pharmacological therapy. Medical pharmacological therapy is mostly represented by drug class benzopyrones, which bind to interstitial proteins, thus inducing phagocytosis and proteolysis. Once being fragmented, they can quickly be reabsorbed by venous capillaries. They may have a role in reducing interstitial edema, softening the limb affected by BCRL, and reducing infection (74, 75). However, they are characterized by hepatotoxicity, and they do not represent the first-line treatment of BCRL. No recent systematic reviews or metanalyses have been found regarding their use in BCRL treatment.

Not enough evidence exists to form a clinical recommendation (29) on therapies such as Cyclo 3® Fort (Cyclo 3® Fort, Pierre Fabre Medicament Laboratories, Boulogne-Billancourt, France), which is a combination of root extract of the Ruscus aculeatus plant, hesperidin methyl chalcone and ascorbic acid (76), electrotherapy (77), Ginkgo biloba (78), pentoxifylline and vitamin E (79).

Complementary medicine. Acupuncture is part of the traditional Chinese medicine, is based on the regulation of energy pathways and circulation through stimulation of specific points on the body surface, as evidenced by neurophysiological investigations, and has been shown effective and safe in a variety of conditions and treatment-related side effects (80). Acupuncture treatments may also include bloodletting, puncturing and cupping, moxibustion, laser needle and electric stimulation. As results from our review, some studies reported that acupuncture provided a significant decrease in reducing arm circumference when compared to physical exercise (6, 81-83), but the same conclusion was not found by other authors (84-86). However, it has been reported that acupuncture intervention is safe and tends to improve the efficacy of other BCRL treatments (84, 87), compared to the single physical exercise or conventional medicine alone (84).

One of the most critical issues in evaluating the effectiveness of acupuncture is the difference in the technique used that is not always described in these studies and the heterogeneity in assessing the patient’s LYE. Indeed, different LYE measurement tools have been used, including the circumference at the height of the elbow or above it, the rim of the most bulging point, the sum of more circumferences calculated at the level of the upper limb, or through the bioimpedance spectrometry measurement. This heterogeneity makes the studies difficult to compare and, therefore, difficult to assess the overall effectiveness of acupuncture treatment. Furthermore, the absence of hidden grouping and blinding method and the reduced sample size produce multiple biases, leading to insufficient evidence of the effectiveness of the acupuncture role in BCRL treatment. Finally, most of the patients who received acupuncture treatment were Asian; thus, no studies represent different ethnic groups (82, 85).

Reflexology bases are, to date, not clarified yet. However, theories rely on the direct pressure on a peripheral nerve of the foot in stimulating a corresponding area of the body, providing relief to a specific symptom (88). Reflexology is also based on oxytocin’s release, improving the circulation through pressure and the input to the central nervous system that perceives the symptoms (89). Regarding BCRL, reflexology has not enough high-level evidence supporting beneficial or detrimental effects on BCRL, despite no adverse effects reported after reflexology intervention. Reflexology seems to improve quality of life acting on fatigue, nausea, and vomiting, but no substantial evidence is available as regards effects on BCRL because of limited numbers and quality of studies (90).

Yoga practice is considered part of the complementary therapies, but also of physical exercise. It is based on meditation, relaxation, breathing, stretching, and posture control exercises to improve muscles and joints status and range of motion. Yoga interventions may help in reducing pain, swelling, limb volume, and tissue fibrosis (27, 35, 91-94). The study by Wei et al. (95) described the effect of different yoga programs, including meditation, warm-up, breathing, exercises, and cooldown, practiced from once to twice a week, with an exercise duration of 60 minutes, for a variable duration from 4 weeks to 6 months of yoga practice. This revision aimed to evaluate if yoga and conventional treatments improved BCRL condition. The measured outcomes were the upper extremity volume, upper limb and grip strength, range of motion, and QoL. Results on BCRL status varied between the studies: some reported that 8-week yoga practice improved LYE and spine mobility but did not report QoL changes; others did not find any change or no significant outcome of the 6-month procedure. Concerns emerging from this investigation are the vast heterogeneity of practice (some studies did not report how the yoga practice was conducted) that make the studies incomparable and not conclusive. It can’t be clearly demonstrated that a yoga intervention may provide significant benefits when added to usual treatment. However, developing a standard yoga protocol may reveal that yoga practice, with 1-2 times a week class session and remaining days with home practice, with 60-minute sessions, and extended up to 8 weeks, could lead to a significant improvement of BCRL, reducing swelling, disability and improving joints and muscles status and function and related range of motion, with a final positive impact on QoL. Panchik et al. described the effect of yoga and other physical exercise practice, claiming a decreased swelling and reduction of BCRL related symptoms (43). However, non-traditional forms of exercise should be further investigated to assess their role in BCRL treatment properly.

Alongside yoga practice, Tai Chi intervention had a beneficial effect on emotional wellbeing and upper limb mobility as well, but the investigated studies presented low methodological quality; thus, careful interpretation of these results is mandatory (27).

Limitations

Almost all conclusions from the studies discussed above should be cautiously taken into account because of the insufficient quality of most published papers on BCRL treatment. Indeed, only bandages and IPC showed a substantial beneficial effect in reducing LYE volume in the acute-intensive phase. At the same time, MLD demonstrated effectiveness when immediately applied after breast surgery or in the early stage of BCRL, but not in overt BCRL.

Despite being burdened by difficult compliance to the treatment, physical exercise remains a milestone in BCRL regarding almost all its modalities (aerobic exercise, resistance exercise, aquatic therapy), reduced upper limb volume, improved upper body strength, and does not affect the development or worsening of LYE. Kinesio taping, PBMT, pharmacological therapy and complementary procedures do not show conclusive effectiveness in BCRL treatment, but patients often seek complementary medicine for symptom relief as other therapies are not beneficial. Finally, surgery is considered the last resort. It may be a symptom treatment (liposuction, reducing volume but not improving the drainage), preventing treatment (LVA, reducing BCRL incidence, improving drainage, useful in BCRL early phase), and curative treatment (VLNT, reducing volume, improving drainage, useful in overt BCRL). At present, no comparison has been made between the effectiveness of a surgical technique against another. Skincare practice is pivotal to prevent infection in association with all concurrent treatments.

This review has certain limitations since the literature search did not include articles before 2016, although many of these and certainly the most important were discussed in the papers examined. Furthermore, the review does not meet the PRISMA criteria for systematic review and included no statistical evaluation because of the impossibility of comparing all the articles discussing substantially different topics. the review is intended as narrative and aims to be an introductory guide for those new to the treatment of BCRL of the upper limb.

Conclusion

In conclusion, BCRL is still to be considered a challenging issue for breast cancer survivors, and there is not a gold-standard treatment. Furthermore, the lack of clinically globally accepted criteria in evaluating BCRL makes it challenging to evaluate BCRL treatment’s effectiveness. As stated by the American Cancer Society and the American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline (48): “It is recommended that primary care clinicians should counsel survivors on how to prevent/reduce the risk of LYE, including weight loss for those who are overweight or obese and should refer patients with clinical symptoms or swelling suggestive of LYE to a therapist knowledgeable about the diagnosis and treatment of LYE, such as a physical therapist, occupational therapist, or LYE specialist.” Knowledge about different treatment options deserves diffusion and the role of medical, physical and surgical treatments always considered to improve QoL of breast cancer survivors.

Footnotes

  • ↵* These Authors contributed equally to the study.

  • This article is freely accessible online.

  • Authors’ Contributions

    Study concept and design: PM and SD. Acquisition, analysis, and interpretation of data: PM, SD, SM, VG. Drafting of the manuscript: PM, SD, DP, SM, VG. Critical revision of the manuscript: all authors. All Authors read and approved the final manuscript.

  • Conflicts of Interest

    All Authors declare that they have no conflicts of interest.

  • Received April 6, 2021.
  • Revision received June 3, 2021.
  • Accepted June 7, 2021.
  • Copyright © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

References

  1. ↵
    1. DiSipio T,
    2. Rye S,
    3. Newman B and
    4. Hayes S
    : Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis. Lancet Oncol 14(6): 500-515, 2013. PMID: 23540561. DOI: 10.1016/S1470-2045(13)70076-7
    OpenUrlCrossRefPubMed
  2. ↵
    1. Ezzo J,
    2. Manheimer E,
    3. McNeely ML,
    4. Howell DM,
    5. Weiss R,
    6. Johansson KI,
    7. Bao T,
    8. Bily L,
    9. Tuppo CM,
    10. Williams AF and
    11. Karadibak D
    : Manual lymphatic drainage for lymphedema following breast cancer treatment. Cochrane Database Syst Rev (5): CD003475, 2015. PMID: 25994425. DOI: 10.1002/14651858.CD003475.pub2
    OpenUrlCrossRefPubMed
  3. ↵
    1. Zou L,
    2. Liu FH,
    3. Shen PP,
    4. Hu Y,
    5. Liu XQ,
    6. Xu YY,
    7. Pen QL,
    8. Wang B,
    9. Zhu YQ and
    10. Tian Y
    : The incidence and risk factors of related lymphedema for breast cancer survivors post-operation: a 2-year follow-up prospective cohort study. Breast Cancer 25(3): 309-314, 2018. PMID: 29397555. DOI: 10.1007/s12282-018-0830-3
    OpenUrlCrossRefPubMed
    1. Ribeiro Pereira ACP,
    2. Koifman RJ and
    3. Bergmann A
    : Incidence and risk factors of lymphedema after breast cancer treatment: 10 years of follow-up. Breast 36: 67-73, 2017. PMID: 28992556. DOI: 10.1016/j.breast.2017.09.006
    OpenUrlCrossRefPubMed
  4. ↵
    1. Fu MR,
    2. Ridner SH,
    3. Hu SH,
    4. Stewart BR,
    5. Cormier JN and
    6. Armer JM
    : Psychosocial impact of lymphedema: a systematic review of literature from 2004 to 2011. Psychooncology 22(7): 1466-1484, 2013. PMID: 23044512. DOI: 10.1002/pon.3201
    OpenUrlCrossRefPubMed
  5. ↵
    1. Liang M,
    2. Chen Q,
    3. Peng K,
    4. Deng L,
    5. He L,
    6. Hou Y,
    7. Zhang Y,
    8. Guo J,
    9. Mei Z and
    10. Li L
    : Manual lymphatic drainage for lymphedema in patients after breast cancer surgery: A systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore) 99(49): e23192, 2020. PMID: 33285693. DOI: 10.1097/MD.0000000000023192
    OpenUrlCrossRefPubMed
  6. ↵
    1. Sekyere M
    : Incidence and risk factors of arm lymphedema following breast cancer treatment. Journal of Global Oncology 4(Suppl 2): 213s-213s, 2020. DOI: 10.1200/jgo.18.85800
    OpenUrlCrossRef
  7. ↵
    1. Paskett ED,
    2. Dean JA,
    3. Oliveri JM and
    4. Harrop JP
    : Cancer-related lymphedema risk factors, diagnosis, treatment, and impact: a review. J Clin Oncol 30(30): 3726-3733, 2012. PMID: 23008299. DOI: 10.1200/JCO.2012.41.8574
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Szolnoky G,
    2. Dobozy A and
    3. Kemény L
    : Towards an effective management of chronic lymphedema. Clin Dermatol 32(5): 685-691, 2014. PMID: 25160111. DOI: 10.1016/j.clindermatol.2014.04.017
    OpenUrlCrossRefPubMed
  9. ↵
    1. Doscher ME,
    2. Herman S and
    3. Garfein ES
    : Surgical management of inoperable lymphedema: the re-emergence of abandoned techniques. J Am Coll Surg 215(2): 278-283, 2012. PMID: 22560317. DOI: 10.1016/j.jamcollsurg.2012.03.020
    OpenUrlCrossRefPubMed
  10. ↵
    1. Cooper G and
    2. Bagnall A
    : Prevalence of lymphoedema in the UK: focus on the southwest and West Midlands. Br J Community Nurs Suppl: S6-14, 2016. PMID: 27046432. DOI: 10.12968/bjcn.2016.21.Sup4.S6
    OpenUrlCrossRefPubMed
  11. ↵
    1. Gebruers N,
    2. Verbelen H,
    3. De Vrieze T,
    4. Coeck D and
    5. Tjalma W
    : Incidence and time path of lymphedema in sentinel node negative breast cancer patients: a systematic review. Arch Phys Med Rehabil 96(6): 1131-1139, 2015. PMID: 25637862. DOI: 10.1016/j.apmr.2015.01.014
    OpenUrlCrossRefPubMed
  12. ↵
    1. Harris SR and
    2. Niesen-Vertommen SL
    : Challenging the myth of exercise-induced lymphedema following breast cancer: a series of case reports. J Surg Oncol 74(2): 95-8; discussion 98-9, 2000. PMID: 10914817. DOI: 10.1002/1096-9098(200006)74:2<95::AID-JSO3>3.0.CO;2-Q
    OpenUrlCrossRefPubMed
  13. ↵
    1. Ahmed RL,
    2. Thomas W,
    3. Yee D and
    4. Schmitz KH
    : Randomized controlled trial of weight training and lymphedema in breast cancer survivors. J Clin Oncol 24(18): 2765-2772, 2006. PMID: 16702582. DOI: 10.1200/JCO.2005.03.6749
    OpenUrlAbstract/FREE Full Text
  14. ↵
    1. Rossi M,
    2. Grassi R,
    3. Costa R,
    4. Di Rosa L,
    5. D’Arpa S,
    6. Moschella F and
    7. Cordova A
    : Evaluation of the upper limb lymphatic system: A prospective lymphoscintigraphic study in melanoma patients and healthy controls. Plast Reconstr Surg 138(6): 1321-1331, 2016. PMID: 27537229. DOI: 10.1097/PRS.0000000000002763
    OpenUrlCrossRefPubMed
  15. ↵
    1. Executive Committee
    : The diagnosis and treatment of peripheral lymphedema: 2016 consensus document of the International Society of Lymphology. Lymphology 49(4): 170-184, 2016. PMID: 29908550.
    OpenUrlPubMed
  16. ↵
    1. Yamamoto T,
    2. Yamamoto N,
    3. Hara H,
    4. Mihara M,
    5. Narushima M and
    6. Koshima I
    : Upper extremity lymphedema index: a simple method for severity evaluation of upper extremity lymphedema. Ann Plast Surg 70(1): 47-49, 2013. PMID: 21734534. DOI: 10.1097/SAP.0b013e3182275d23
    OpenUrlCrossRefPubMed
  17. ↵
    1. Shah C,
    2. Arthur DW,
    3. Wazer D,
    4. Khan A,
    5. Ridner S and
    6. Vicini F
    : The impact of early detection and intervention of breast cancer-related lymphedema: a systematic review. Cancer Med 5(6): 1154-1162, 2016. PMID: 26993371. DOI: 10.1002/cam4.691
    OpenUrlCrossRefPubMed
  18. ↵
    1. Berlit S,
    2. Brade J,
    3. Tuschy B,
    4. Hornemann A,
    5. Leweling H,
    6. Eghardt V and
    7. Sütterlin M
    : Comparing bioelectrical impedance values in assessing early upper limb lymphedema after breast cancer surgery. In Vivo 26(5): 863-867, 2012. PMID: 22949603.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    1. Lasinski BB,
    2. McKillip Thrift K,
    3. Squire D,
    4. Austin MK,
    5. Smith KM,
    6. Wanchai A,
    7. Green JM,
    8. Stewart BR,
    9. Cormier JN and
    10. Armer JM
    : A systematic review of the evidence for complete decongestive therapy in the treatment of lymphedema from 2004 to 2011. PM R 4(8): 580-601, 2012. PMID: 22920313. DOI: 10.1016/j.pmrj.2012.05.003
    OpenUrlCrossRefPubMed
  20. ↵
    1. Ginsburg O,
    2. Bray F,
    3. Coleman MP,
    4. Vanderpuye V,
    5. Eniu A,
    6. Kotha SR,
    7. Sarker M,
    8. Huong TT,
    9. Allemani C,
    10. Dvaladze A,
    11. Gralow J,
    12. Yeates K,
    13. Taylor C,
    14. Oomman N,
    15. Krishnan S,
    16. Sullivan R,
    17. Kombe D,
    18. Blas MM,
    19. Parham G,
    20. Kassami N and
    21. Conteh L
    : The global burden of women’s cancers: a grand challenge in global health. Lancet 389(10071): 847-860, 2017. PMID: 27814965. DOI: 10.1016/S0140-6736(16)31392-7
    OpenUrlCrossRefPubMed
  21. ↵
    1. Global Burden of Disease Cancer Collaboration, Fitzmaurice C,
    2. Allen C,
    3. Barber RM,
    4. Barregard L,
    5. Bhutta ZA,
    6. Brenner H,
    7. Dicker DJ,
    8. Chimed-Orchir O,
    9. Dandona R,
    10. Dandona L,
    11. Fleming T,
    12. Forouzanfar MH,
    13. Hancock J,
    14. Hay RJ,
    15. Hunter-Merrill R,
    16. Huynh C,
    17. Hosgood HD,
    18. Johnson CO,
    19. Jonas JB,
    20. Khubchandani J,
    21. Kumar GA,
    22. Kutz M,
    23. Lan Q,
    24. Larson HJ,
    25. Liang X,
    26. Lim SS,
    27. Lopez AD,
    28. MacIntyre MF,
    29. Marczak L,
    30. Marquez N,
    31. Mokdad AH,
    32. Pinho C,
    33. Pourmalek F,
    34. Salomon JA,
    35. Sanabria JR,
    36. Sandar L,
    37. Sartorius B,
    38. Schwartz SM,
    39. Shackelford KA,
    40. Shibuya K,
    41. Stanaway J,
    42. Steiner C,
    43. Sun J,
    44. Takahashi K,
    45. Vollset SE,
    46. Vos T,
    47. Wagner JA,
    48. Wang H,
    49. Westerman R,
    50. Zeeb H,
    51. Zoeckler L,
    52. Abd-Allah F,
    53. Ahmed MB,
    54. Alabed S,
    55. Alam NK,
    56. Aldhahri SF,
    57. Alem G,
    58. Alemayohu MA,
    59. Ali R,
    60. Al-Raddadi R,
    61. Amare A,
    62. Amoako Y,
    63. Artaman A,
    64. Asayesh H,
    65. Atnafu N,
    66. Awasthi A,
    67. Saleem HB,
    68. Barac A,
    69. Bedi N,
    70. Bensenor I,
    71. Berhane A,
    72. Bernabé E,
    73. Betsu B,
    74. Binagwaho A,
    75. Boneya D,
    76. Campos-Nonato I,
    77. Castañeda-Orjuela C,
    78. Catalá-López F,
    79. Chiang P,
    80. Chibueze C,
    81. Chitheer A,
    82. Choi JY,
    83. Cowie B,
    84. Damtew S,
    85. das Neves J,
    86. Dey S,
    87. Dharmaratne S,
    88. Dhillon P,
    89. Ding E,
    90. Driscoll T,
    91. Ekwueme D,
    92. Endries AY,
    93. Farvid M,
    94. Farzadfar F,
    95. Fernandes J,
    96. Fischer F,
    97. G/Hiwot TT,
    98. Gebru A,
    99. Gopalani S,
    100. Hailu A,
    101. Horino M,
    102. Horita N,
    103. Husseini A,
    104. Huybrechts I,
    105. Inoue M,
    106. Islami F,
    107. Jakovljevic M,
    108. James S,
    109. Javanbakht M,
    110. Jee SH,
    111. Kasaeian A,
    112. Kedir MS,
    113. Khader YS,
    114. Khang YH,
    115. Kim D,
    116. Leigh J,
    117. Linn S,
    118. Lunevicius R,
    119. El Razek HMA,
    120. Malekzadeh R,
    121. Malta DC,
    122. Marcenes W,
    123. Markos D,
    124. Melaku YA,
    125. Meles KG,
    126. Mendoza W,
    127. Mengiste DT,
    128. Meretoja TJ,
    129. Miller TR,
    130. Mohammad KA,
    131. Mohammadi A,
    132. Mohammed S,
    133. Moradi-Lakeh M,
    134. Nagel G,
    135. Nand D,
    136. Le Nguyen Q,
    137. Nolte S,
    138. Ogbo FA,
    139. Oladimeji KE,
    140. Oren E,
    141. Pa M,
    142. Park EK,
    143. Pereira DM,
    144. Plass D,
    145. Qorbani M,
    146. Radfar A,
    147. Rafay A,
    148. Rahman M,
    149. Rana SM,
    150. Søreide K,
    151. Satpathy M,
    152. Sawhney M,
    153. Sepanlou SG,
    154. Shaikh MA,
    155. She J,
    156. Shiue I,
    157. Shore HR,
    158. Shrime MG,
    159. So S,
    160. Soneji S,
    161. Stathopoulou V,
    162. Stroumpoulis K,
    163. Sufiyan MB,
    164. Sykes BL,
    165. Tabarés-Seisdedos R,
    166. Tadese F,
    167. Tedla BA,
    168. Tessema GA,
    169. Thakur JS,
    170. Tran BX,
    171. Ukwaja KN,
    172. Uzochukwu BSC,
    173. Vlassov VV,
    174. Weiderpass E,
    175. Wubshet Terefe M,
    176. Yebyo HG,
    177. Yimam HH,
    178. Yonemoto N,
    179. Younis MZ,
    180. Yu C,
    181. Zaidi Z,
    182. Zaki MES,
    183. Zenebe ZM,
    184. Murray CJL and
    185. Naghavi M
    : Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: A systematic analysis for the Global Burden of Disease study. JAMA Oncol 3(4): 524-548, 2017. PMID: 27918777. DOI: 10.1001/jamaoncol.2016.5688
    OpenUrlCrossRefPubMed
  22. ↵
    1. International Society of Lymphology
    : The diagnosis and treatment of peripheral lymphedema: 2013 Consensus Document of the International Society of Lymphology. Lymphology 46(1): 1-11, 2013. PMID: 23930436.
    OpenUrlPubMed
  23. ↵
    1. Kasseroller RG
    : The Vodder School: the Vodder method. Cancer 83(12 Suppl American): 2840-2842, 1998. PMID: 9874409. DOI: 10.1002/(sici)1097-0142(19981215)83:12b+<2840::aid-cncr37>3.0.co;2-5
    OpenUrlCrossRefPubMed
  24. ↵
    1. Földi M
    : Anatomical and physiological basis for physical therapy of lymphedema. Experientia Suppl 33: 15-18, 1978. PMID: 282150.
    OpenUrlPubMed
  25. ↵
    1. Müller M,
    2. Klingberg K,
    3. Wertli MM and
    4. Carreira H
    : Manual lymphatic drainage and quality of life in patients with lymphoedema and mixed oedema: a systematic review of randomised controlled trials. Qual Life Res 27(6): 1403-1414, 2018. PMID: 29404923. DOI: 10.1007/s11136-018-1796-5
    OpenUrlCrossRefPubMed
  26. ↵
    1. Olsson Möller U,
    2. Beck I,
    3. Rydén L and
    4. Malmström M
    : A comprehensive approach to rehabilitation interventions following breast cancer treatment - a systematic review of systematic reviews. BMC Cancer 19(1): 472, 2019. PMID: 31109309. DOI: 10.1186/s12885-019-5648-7
    OpenUrlCrossRefPubMed
  27. ↵
    1. Shao Y and
    2. Zhong DS
    : Manual lymphatic drainage for breast cancer-related lymphoedema. Eur J Cancer Care (Engl) 26(5), 2017. PMID: 27167238. DOI: 10.1111/ecc.12517
    OpenUrlCrossRefPubMed
  28. ↵
    1. Greenlee H,
    2. DuPont-Reyes MJ,
    3. Balneaves LG,
    4. Carlson LE,
    5. Cohen MR,
    6. Deng G,
    7. Johnson JA,
    8. Mumber M,
    9. Seely D,
    10. Zick SM,
    11. Boyce LM and
    12. Tripathy D
    : Clinical practice guidelines on the evidence-based use of integrative therapies during and after breast cancer treatment. CA Cancer J Clin 67(3): 194-232, 2017. PMID: 28436999. DOI: 10.3322/caac.21397
    OpenUrlCrossRefPubMed
  29. ↵
    1. Zimmermann A,
    2. Wozniewski M,
    3. Szklarska A,
    4. Lipowicz A and
    5. Szuba A
    : Efficacy of manual lymphatic drainage in preventing secondary lymphedema after breast cancer surgery. Lymphology 45(3): 103-112, 2012. PMID: 23342930.
    OpenUrlPubMed
  30. ↵
    1. Smile TD,
    2. Tendulkar R,
    3. Schwarz G,
    4. Arthur D,
    5. Grobmyer S,
    6. Valente S,
    7. Vicini F and
    8. Shah C
    : A review of treatment for breast cancer-related lymphedema: Paradigms for clinical practice. Am J Clin Oncol 41(2): 178-190, 2018. PMID: 28009597. DOI: 10.1097/COC.0000000000000355
    OpenUrlCrossRefPubMed
  31. ↵
    1. Jeffs E,
    2. Ream E,
    3. Taylor C and
    4. Bick D
    : Clinical effectiveness of decongestive treatments on excess arm volume and patient-centered outcomes in women with early breast cancer-related arm lymphedema: a systematic review. JBI Database System Rev Implement Rep 16(2): 453-506, 2018. PMID: 29419623. DOI: 10.11124/JBISRIR-2016-003185
    OpenUrlCrossRefPubMed
  32. ↵
    1. D’Egidio V,
    2. Sestili C,
    3. Mancino M,
    4. Sciarra I,
    5. Cocchiara R,
    6. Backhaus I,
    7. Mannocci A,
    8. De Luca A,
    9. Frusone F,
    10. Monti M,
    11. La Torre G and RETURN TO BREAST Collaborative group
    : Counseling interventions delivered in women with breast cancer to improve health-related quality of life: a systematic review. Qual Life Res 26(10): 2573-2592, 2017. PMID: 28623442. DOI: 10.1007/s11136-017-1613-6
    OpenUrlCrossRefPubMed
  33. ↵
    1. Tambour M,
    2. Holt M,
    3. Speyer A,
    4. Christensen R and
    5. Gram B
    : Manual lymphatic drainage adds no further volume reduction to Complete Decongestive Therapy on breast cancer-related lymphoedema: a multicentre, randomised, single-blind trial. Br J Cancer 119(10): 1215-1222, 2018. PMID: 30353049. DOI: 10.1038/s41416-018-0306-4
    OpenUrlCrossRefPubMed
  34. ↵
    1. Rogan S,
    2. Taeymans J,
    3. Luginbuehl H,
    4. Aebi M,
    5. Mahnig S and
    6. Gebruers N
    : Therapy modalities to reduce lymphoedema in female breast cancer patients: a systematic review and meta-analysis. Breast Cancer Res Treat 159(1): 1-14, 2016. PMID: 27460637. DOI: 10.1007/s10549-016-3919-4
    OpenUrlCrossRefPubMed
  35. ↵
    1. Cendron S,
    2. Paiva L,
    3. Darski C and
    4. Colla C
    : Fisioterapia Complexa Descongestiva Associada a Terapias de Compressão no Tratamento do Linfedema Secundário ao Câncer de Mama: uma Revisão Sistemática. Revista Brasileira de Cancerologia 61(1): 49-58, 2020. DOI: 10.32635/2176-9745.RBC.2015v61n1.773
    OpenUrlCrossRef
  36. ↵
    1. Pinheiro M dos S,
    2. Godoy AC and
    3. Sunemi MM de O
    : Kinesio Taping associado à drenagem linfática manual no linfedema pós mastectomia: Relato de caso. Fisioter Saúde Func 4: 30-36, 2015.
    OpenUrl
  37. ↵
    1. Kasawara KT,
    2. Mapa JMR,
    3. Ferreira V,
    4. Added MAN,
    5. Shiwa SR,
    6. Carvas N Jr. and
    7. Batista PA
    : Effects of Kinesio Taping on breast cancer-related lymphedema: A meta-analysis in clinical trials. Physiother Theory Pract 34(5): 337-345, 2018. PMID: 29308967. DOI: 10.1080/09593985.2017.1419522
    OpenUrlCrossRefPubMed
  38. ↵
    1. Furmaniak AC,
    2. Menig M and
    3. Markes MH
    : Exercise for women receiving adjuvant therapy for breast cancer. Cochrane Database Syst Rev 9: CD005001, 2016. PMID: 27650122. DOI: 10.1002/14651858.CD005001.pub3
    OpenUrlCrossRefPubMed
  39. ↵
    1. Devoogdt N,
    2. Geraerts I,
    3. Van Kampen M,
    4. De Vrieze T,
    5. Vos L,
    6. Neven P,
    7. Vergote I,
    8. Christiaens MR,
    9. Thomis S and
    10. De Groef A
    : Manual lymph drainage may not have a preventive effect on the development of breast cancer-related lymphoedema in the long term: a randomised trial. J Physiother 64(4): 245-254, 2018. PMID: 30241913. DOI: 10.1016/j.jphys.2018.08.007
    OpenUrlCrossRefPubMed
  40. ↵
    1. Wahid A,
    2. Manek N,
    3. Nichols M,
    4. Kelly P,
    5. Foster C,
    6. Webster P,
    7. Kaur A,
    8. Friedemann Smith C,
    9. Wilkins E,
    10. Rayner M,
    11. Roberts N and
    12. Scarborough P
    : Quantifying the association between physical activity and cardiovascular disease and diabetes: a systematic review and meta-analysis. J Am Heart Assoc 5(9): e002495, 2016. PMID: 27628572. DOI: 10.1161/JAHA.115.002495
    OpenUrlAbstract/FREE Full Text
  41. ↵
    1. Baumann FT,
    2. Reike A,
    3. Reimer V,
    4. Schumann M,
    5. Hallek M,
    6. Taaffe DR,
    7. Newton RU and
    8. Galvao DA
    : Effects of physical exercise on breast cancer-related secondary lymphedema: a systematic review. Breast Cancer Res Treat 170(1): 1-13, 2018. PMID: 29470804. DOI: 10.1007/s10549-018-4725-y
    OpenUrlCrossRefPubMed
  42. ↵
    1. Panchik D,
    2. Masco S,
    3. Zinnikas P,
    4. Hillriegel B,
    5. Lauder T,
    6. Suttmann E,
    7. Chinchilli V,
    8. McBeth M and
    9. Hermann W
    : Effect of exercise on breast cancer-related lymphedema: What the lymphatic surgeon needs to know. J Reconstr Microsurg 35(1): 37-45, 2019. PMID: 29935493. DOI: 10.1055/s-0038-1660832
    OpenUrlCrossRefPubMed
  43. ↵
    1. Morgulec-adamowicz N,
    2. Marszałek J and
    3. Jagustyn P
    : Nordic walking - A new form of adapted physical activity (a literature review). Human Movement 12(2), 2019. DOI: 10.2478/v10038-011-0009-7
    OpenUrlCrossRef
  44. ↵
    1. Sánchez-Lastra MA,
    2. Torres J,
    3. Martínez-Lemos I and
    4. Ayán C
    : Nordic walking for women with breast cancer: A systematic review. Eur J Cancer Care (Engl) 28(6): e13130, 2019. PMID: 31389108. DOI: 10.1111/ecc.13130
    OpenUrlCrossRefPubMed
  45. ↵
    1. Hasenoehrl T,
    2. Keilani M,
    3. Palma S and
    4. Crevenna R
    : Resistance exercise and breast cancer related lymphedema - a systematic review update. Disabil Rehabil 42(1): 26-35, 2020. PMID: 30638093. DOI: 10.1080/09638288.2018.1514663
    OpenUrlCrossRefPubMed
    1. Keilani M,
    2. Hasenoehrl T,
    3. Neubauer M and
    4. Crevenna R
    : Resistance exercise and secondary lymphedema in breast cancer survivors-a systematic review. Support Care Cancer 24(4): 1907-1916, 2016. PMID: 26715294. DOI: 10.1007/s00520-015-3068-z
    OpenUrlCrossRefPubMed
  46. ↵
    1. Runowicz CD,
    2. Leach CR,
    3. Henry NL,
    4. Henry KS,
    5. Mackey HT,
    6. Cowens-Alvarado RL,
    7. Cannady RS,
    8. Pratt-Chapman ML,
    9. Edge SB,
    10. Jacobs LA,
    11. Hurria A,
    12. Marks LB,
    13. LaMonte SJ,
    14. Warner E,
    15. Lyman GH and
    16. Ganz PA
    : American Cancer Society/American Society of Clinical Oncology breast cancer survivorship care guideline. J Clin Oncol 34(6): 611-635, 2016. PMID: 26644543. DOI: 10.1200/JCO.2015.64.3809
    OpenUrlAbstract/FREE Full Text
  47. ↵
    1. Montaño-Rojas LS,
    2. Romero-Pérez EM,
    3. Medina-Pérez C,
    4. Reguera-García MM and
    5. de Paz JA
    : Resistance training in breast cancer survivors: A systematic review of exercise programs. Int J Environ Res Public Health 17(18): 6511, 2020. PMID: 32906761. DOI: 10.3390/ijerph17186511
    OpenUrlCrossRefPubMed
  48. ↵
    1. Hasenoehrl T,
    2. Palma S,
    3. Ramazanova D,
    4. Kölbl H,
    5. Dorner TE,
    6. Keilani M and
    7. Crevenna R
    : Resistance exercise and breast cancer-related lymphedema-a systematic review update and meta-analysis. Support Care Cancer 28(8): 3593-3603, 2020. PMID: 32415386. DOI: 10.1007/s00520-020-05521-x
    OpenUrlCrossRefPubMed
  49. ↵
    1. Cho Y,
    2. Do J,
    3. Jung S,
    4. Kwon O and
    5. Jeon JY
    : Effects of a physical therapy program combined with manual lymphatic drainage on shoulder function, quality of life, lymphedema incidence, and pain in breast cancer patients with axillary web syndrome following axillary dissection. Support Care Cancer 24(5): 2047-2057, 2016. PMID: 26542271. DOI: 10.1007/s00520-015-3005-1
    OpenUrlCrossRefPubMed
  50. ↵
    1. Nelson NL
    : Breast cancer-related lymphedema and resistance exercise: A systematic review. J Strength Cond Res 30(9): 2656-2665, 2016. PMID: 26840439. DOI: 10.1519/JSC.0000000000001355
    OpenUrlCrossRefPubMed
  51. ↵
    1. Yeung W and
    2. Semciw AI
    : Aquatic therapy for people with lymphedema: A systematic review and meta-analysis. Lymphat Res Biol 16(1): 9-19, 2018. PMID: 28346851. DOI: 10.1089/lrb.2016.0056
    OpenUrlCrossRefPubMed
  52. ↵
    1. Vignes S and
    2. Trévidic P
    : Role of surgery in the treatment of lymphedema. Rev Med Interne 23(Suppl 3): 426s-430s, 2002. PMID: 12162208. DOI: 10.1016/s0248-8663(02)80387-3
    OpenUrlCrossRefPubMed
  53. ↵
    1. Campisi C,
    2. Bellini C,
    3. Campisi C,
    4. Accogli S,
    5. Bonioli E and
    6. Boccardo F
    : Microsurgery for lymphedema: clinical research and long-term results. Microsurgery 30(4): 256-260, 2010. PMID: 20235160. DOI: 10.1002/micr.20737
    OpenUrlCrossRefPubMed
  54. ↵
    1. Brorson H,
    2. Svensson H,
    3. Norrgren K and
    4. Thorsson O
    : Liposuction reduces arm lymphedema without significantly altering the already impaired lymph transport. Lymphology 31(4): 156-172, 1998. PMID: 9949387.
    OpenUrlPubMed
  55. ↵
    1. Campisi C and
    2. Boccardo F
    : Microsurgical techniques for lymphedema treatment: derivative lymphatic-venous microsurgery. World J Surg 28(6): 609-613, 2004. PMID: 15366754. DOI: 10.1007/s00268-004-7252-4
    OpenUrlCrossRefPubMed
  56. ↵
    1. Nagase T,
    2. Gonda K,
    3. Inoue K,
    4. Higashino T,
    5. Fukuda N,
    6. Gorai K,
    7. Mihara M,
    8. Nakanishi M and
    9. Koshima I
    : Treatment of lymphedema with lymphaticovenular anastomoses. Int J Clin Oncol 10(5): 304-310, 2005. PMID: 16247656. DOI: 10.1007/s10147-005-0518-5
    OpenUrlCrossRefPubMed
  57. ↵
    1. Lee BB,
    2. Laredo J and
    3. Neville R
    : Current status of lymphatic reconstructive surgery for chronic lymphedema: it is still an uphill battle! Int J Angiol 20(2): 73-80, 2011. PMID: 22654468. DOI: 10.1055/s-0031-1279685
    OpenUrlCrossRefPubMed
  58. ↵
    1. Becker C,
    2. Assouad J,
    3. Riquet M and
    4. Hidden G
    : Postmastectomy lymphedema: long-term results following microsurgical lymph node transplantation. Ann Surg 243(3): 313-315, 2006. PMID: 16495693. DOI: 10.1097/01.sla.0000201258.10304.16
    OpenUrlCrossRefPubMed
  59. ↵
    1. Markkula SP,
    2. Leung N,
    3. Allen VB and
    4. Furniss D
    : Surgical interventions for the prevention or treatment of lymphoedema after breast cancer treatment. Cochrane Database Syst Rev 2: CD011433, 2019. PMID: 30779124. DOI: 10.1002/14651858.CD011433.pub2
    OpenUrlCrossRefPubMed
  60. ↵
    1. Bulley C,
    2. Coutts F,
    3. Blyth C,
    4. Jack W,
    5. Chetty U,
    6. Barber M and
    7. Tan CW
    : A Morbidity Screening Tool for identifying fatigue, pain, upper limb dysfunction and lymphedema after breast cancer treatment: a validity study. Eur J Oncol Nurs 18(2): 218-227, 2014. PMID: 24246445. DOI: 10.1016/j.ejon.2013.10.006
    OpenUrlCrossRefPubMed
  61. ↵
    1. Boccardo FM,
    2. Ansaldi F,
    3. Bellini C,
    4. Accogli S,
    5. Taddei G,
    6. Murdaca G,
    7. Campisi CC,
    8. Villa G,
    9. Icardi G,
    10. Durando P,
    11. Puppo F and
    12. Campisi C
    : Prospective evaluation of a prevention protocol for lymphedema following surgery for breast cancer. Lymphology 42(1): 1-9, 2009. PMID: 19499762.
    OpenUrlPubMed
  62. ↵
    1. Boccardo FM,
    2. Casabona F,
    3. Friedman D,
    4. Puglisi M,
    5. De Cian F,
    6. Ansaldi F and
    7. Campisi C
    : Surgical prevention of arm lymphedema after breast cancer treatment. Ann Surg Oncol 18(9): 2500-2505, 2011. PMID: 21369739. DOI: 10.1245/s10434-011-1624-4
    OpenUrlCrossRefPubMed
  63. ↵
    1. Dionyssiou D,
    2. Demiri E,
    3. Tsimponis A,
    4. Sarafis A,
    5. Mpalaris V,
    6. Tatsidou G and
    7. Arsos G
    : A randomized control study of treating secondary stage II breast cancer-related lymphoedema with free lymph node transfer. Breast Cancer Res Treat 156(1): 73-79, 2016. PMID: 26895326. DOI: 10.1007/s10549-016-3716-0
    OpenUrlCrossRefPubMed
  64. ↵
    1. Ozturk CN,
    2. Ozturk C,
    3. Glasgow M,
    4. Platek M,
    5. Ashary Z,
    6. Kuhn J,
    7. Aronoff N,
    8. Lohman R,
    9. Djohan R and
    10. Gurunluoglu R
    : Free vascularized lymph node transfer for treatment of lymphedema: A systematic evidence based review. J Plast Reconstr Aesthet Surg 69(9): 1234-1247, 2016. PMID: 27425000. DOI: 10.1016/j.bjps.2016.06.022
    OpenUrlCrossRefPubMed
  65. ↵
    1. Classen DA and
    2. Irvine L
    : Free muscle flap transfer as a lymphatic bridge for upper extremity lymphedema. J Reconstr Microsurg 21(2): 93-99, 2005. PMID: 15739144. DOI: 10.1055/s-2005-864841
    OpenUrlCrossRefPubMed
  66. ↵
    1. Yan A,
    2. Avraham T,
    3. Zampell JC,
    4. Aschen SZ and
    5. Mehrara BJ
    : Mechanisms of lymphatic regeneration after tissue transfer. PLoS One 6(2): e17201, 2011. PMID: 21359148. DOI: 10.1371/journal.pone.0017201
    OpenUrlCrossRefPubMed
  67. ↵
    1. Siotos C,
    2. Hassanein AH,
    3. Bello RJ,
    4. Sebai ME,
    5. Seal SM,
    6. Manahan MA,
    7. Cooney DS,
    8. Cooney CM and
    9. Rosson GD
    : Delayed breast reconstruction on patients with upper extremity lymphedema: a systematic review of the literature and pooled analysis. Ann Plast Surg 81(6): 730-735, 2018. PMID: 29944525. DOI: 10.1097/SAP.0000000000001542
    OpenUrlCrossRefPubMed
  68. ↵
    1. Chen HY,
    2. Tsai HH,
    3. Tam KW and
    4. Huang TW
    : Effects of photobiomodualtion therapy on breast cancer-related lymphoedema: A systematic review and meta-analysis of randomised controlled trials. Complement Ther Med 47: 102200, 2019. PMID: 31780036. DOI: 10.1016/j.ctim.2019.102200
    OpenUrlCrossRefPubMed
  69. ↵
    1. E Lima MT,
    2. E Lima JG,
    3. de Andrade MF and
    4. Bergmann A
    : Low-level laser therapy in secondary lymphedema after breast cancer: systematic review. Lasers Med Sci 29(3): 1289-1295, 2014. PMID: 23192573. DOI: 10.1007/s10103-012-1240-y
    OpenUrlCrossRefPubMed
  70. ↵
    1. Posten W,
    2. Wrone DA,
    3. Dover JS,
    4. Arndt KA,
    5. Silapunt S and
    6. Alam M
    : Low-level laser therapy for wound healing: mechanism and efficacy. Dermatol Surg 31(3): 334-340, 2005. PMID: 15841638. DOI: 10.1111/j.1524-4725.2005.31086
    OpenUrlCrossRefPubMed
  71. ↵
    1. Baxter GD,
    2. Liu L,
    3. Petrich S,
    4. Gisselman AS,
    5. Chapple C,
    6. Anders JJ and
    7. Tumilty S
    : Low level laser therapy (Photobiomodulation therapy) for breast cancer-related lymphedema: a systematic review. BMC Cancer 17(1): 833, 2017. PMID: 29216916. DOI: 10.1186/s12885-017-3852-x
    OpenUrlCrossRefPubMed
  72. ↵
    1. Harris SR,
    2. Hugi MR,
    3. Olivotto IA,
    4. Levine M and Steering Committee for Clinical Practice Guidelines for the Care and Treatment of Breast Cancer
    : Clinical practice guidelines for the care and treatment of breast cancer: 11. Lymphedema. CMAJ 164(2): 191-199, 2001. PMID: 11332311.
    OpenUrlAbstract/FREE Full Text
  73. ↵
    1. Cheifetz O,
    2. Haley L and Breast Cancer Action
    : Management of secondary lymphedema related to breast cancer. Can Fam Physician 56(12): 1277-1284, 2010. PMID: 21375063.
    OpenUrlAbstract/FREE Full Text
  74. ↵
    1. Cluzan RV,
    2. Alliot F,
    3. Ghabboun S and
    4. Pascot M
    : Treatment of secondary lymphedema of the upper limb with CYCLO 3 FORT. Lymphology 29(1): 29-35, 1996. PMID: 8721977.
    OpenUrlPubMed
  75. ↵
    1. Belmonte R,
    2. Tejero M,
    3. Ferrer M,
    4. Muniesa JM,
    5. Duarte E,
    6. Cunillera O and
    7. Escalada F
    : Efficacy of low-frequency low-intensity electrotherapy in the treatment of breast cancer-related lymphoedema: a cross-over randomized trial. Clin Rehabil 26(7): 607-618, 2012. PMID: 22172923. DOI: 10.1177/0269215511427414
    OpenUrlCrossRefPubMed
  76. ↵
    1. Cluzan RV,
    2. Pecking AP,
    3. Mathiex-Fortunet H and
    4. Léger Picherit E
    : Efficacy of BN165 (Ginkor Fort) in breast cancer related upper limb lymphedema: a preliminary study. Lymphology 37(2): 47-52, 2004. PMID: 15328756.
    OpenUrlPubMed
  77. ↵
    1. Gothard L,
    2. Cornes P,
    3. Earl J,
    4. Hall E,
    5. MacLaren J,
    6. Mortimer P,
    7. Peacock J,
    8. Peckitt C,
    9. Woods M and
    10. Yarnold J
    : Double-blind placebo-controlled randomised trial of vitamin E and pentoxifylline in patients with chronic arm lymphoedema and fibrosis after surgery and radiotherapy for breast cancer. Radiother Oncol 73(2): 133-139, 2004. PMID: 15542159. DOI: 10.1016/j.radonc.2004.09.013
    OpenUrlCrossRefPubMed
  78. ↵
    1. Joshi N and
    2. Araque H
    : Neurophysiologic basis for the relief of human pain by acupuncture. Acupunct Electrother Res 34(3-4): 165-174, 2009. PMID: 20344884. DOI: 10.3727/036012909803861022
    OpenUrlCrossRefPubMed
  79. ↵
    1. Jang S,
    2. Ko Y,
    3. Sasaki Y,
    4. Park S,
    5. Jo J,
    6. Kang NH,
    7. Yoo ES,
    8. Park NC,
    9. Cho SH,
    10. Jang H,
    11. Jang BH,
    12. Hwang DS and
    13. Ko SG
    : Acupuncture as an adjuvant therapy for management of treatment-related symptoms in breast cancer patients: Systematic review and meta-analysis (PRISMA-compliant). Medicine (Baltimore) 99(50): e21820, 2020. PMID: 33327222. DOI: 10.1097/MD.0000000000021820
    OpenUrlCrossRefPubMed
  80. ↵
    1. Zhang X,
    2. Wang X,
    3. Zhang B,
    4. Yang S and
    5. Liu D
    : Effects of acupuncture on breast cancer-related lymphoedema: a systematic review and meta-analysis of randomised controlled trials. Acupunct Med 37(1): 16-24, 2019. PMID: 30845813. DOI: 10.1136/acupmed-2018-011668
    OpenUrlCrossRefPubMed
  81. ↵
    1. Zhan Jing L
    : Clinical observation of abdominal acupuncture combining with upper limb functional exercise in treatment of patients with breast cancer-related upper limb lymphoedema. Chin J Woman Child Health Res 28: 570-572, 2017.
    OpenUrl
  82. ↵
    1. Hou W,
    2. Pei L,
    3. Song Y,
    4. Wu J,
    5. Geng H,
    6. Chen L,
    7. Wang Y,
    8. Hu Y,
    9. Zhou J and
    10. Sun J
    : Acupuncture therapy for breast cancer-related lymphedema: A systematic review and meta-analysis. J Obstet Gynaecol Res 45(12): 2307-2317, 2019. PMID: 31608558. DOI: 10.1111/jog.14122
    OpenUrlCrossRefPubMed
  83. ↵
    1. Kim TH,
    2. Kang JW and
    3. Lee MS
    : Current evidence of acupuncture for symptoms related to breast cancer survivors: A PRISMA-compliant systematic review of clinical studies in Korea. Medicine (Baltimore) 97(32): e11793, 2018. PMID: 30095640. DOI: 10.1097/MD.0000000000011793
    OpenUrlCrossRefPubMed
  84. ↵
    1. Bao T,
    2. Iris Zhi W,
    3. Vertosick EA,
    4. Li QS,
    5. DeRito J,
    6. Vickers A,
    7. Cassileth BR,
    8. Mao JJ and
    9. Van Zee KJ
    : Acupuncture for breast cancer-related lymphedema: a randomized controlled trial. Breast Cancer Res Treat 170(1): 77-87, 2018. PMID: 29520533. DOI: 10.1007/s10549-018-4743-9
    OpenUrlCrossRefPubMed
  85. ↵
    1. Chien TJ,
    2. Liu CY and
    3. Fang CJ
    : The effect of acupuncture in breast cancer-related lymphoedema (BCRL): A systematic review and meta-analysis. Integr Cancer Ther 18: 1534735419866910, 2019. PMID: 31387468. DOI: 10.1177/1534735419866910
    OpenUrlCrossRefPubMed
  86. ↵
    1. Luo Z,
    2. Wang L,
    3. Sikorskii A and
    4. Wyatt G
    : Healthcare service utilization and work-related productivity in reflexology intervention for advanced breast cancer women. Support Care Cancer 27(8): 2837-2847, 2019. PMID: 30552595. DOI: 10.1007/s00520-018-4592-4
    OpenUrlCrossRefPubMed
  87. ↵
    Modern Institute of Reflexology. Available at: http://reflexologyinstitute.com/faq_student1.php [Last accessed on March 20, 2021]
  88. ↵
    1. Wanchai A and
    2. Armer JM
    : A systematic review association of reflexology in managing symptoms and side effects of breast cancer treatment. Complement Ther Clin Pract 38: 101074, 2020. PMID: 31783340. DOI: 10.1016/j.ctcp.2019.101074
    OpenUrlCrossRefPubMed
  89. ↵
    1. Parshad O
    : Role of yoga in stress management. West Indian Med J 53(3): 191-194, 2004. PMID: 15352751.
    OpenUrlPubMed
    1. Ross A and
    2. Thomas S
    : The health benefits of yoga and exercise: a review of comparison studies. J Altern Complement Med 16(1): 3-12, 2010. PMID: 20105062. DOI: 10.1089/acm.2009.0044
    OpenUrlCrossRefPubMed
    1. Narahari SR,
    2. Aggithaya MG,
    3. Thernoe L,
    4. Bose KS and
    5. Ryan TJ
    : Yoga protocol for treatment of breast cancer-related lymphedema. Int J Yoga 9(2): 145-155, 2016. PMID: 27512322. DOI: 10.4103/0973-6131.183713
    OpenUrlCrossRefPubMed
  90. ↵
    1. Narahari SR,
    2. Ryan TJ,
    3. Mahadevan PE,
    4. Bose KS and
    5. Prasanna KS
    : Integrated management of filarial lymphedema for rural communities. Lymphology 40(1): 3-13, 2007. PMID: 17539459.
    OpenUrlPubMed
  91. ↵
    1. Wei CW,
    2. Wu YC,
    3. Chen PY,
    4. Chen PE,
    5. Chi CC and
    6. Tung TH
    : Effectiveness of yoga interventions in breast cancer-related lymphedema: a systematic review. Complement Ther Clin Pract 36: 49-55, 2019. PMID: 31383443. DOI: 10.1016/j.ctcp.2019.05.004
    OpenUrlCrossRefPubMed
    1. Torgbenu E,
    2. Luckett T,
    3. Buhagiar MA,
    4. Chang S and
    5. Phillips JL
    : Prevalence and incidence of cancer related lymphedema in low and middle-income countries: a systematic review and meta-analysis. BMC Cancer 20(1): 604, 2020. PMID: 32600278. DOI: 10.1186/s12885-020-07079-7
    OpenUrlCrossRefPubMed
    1. De Vrieze T,
    2. Nevelsteen I,
    3. Thomis S,
    4. De Groef A,
    5. Tjalma WAA,
    6. Gebruers N and
    7. Devoogdt N
    : What are the economic burden and costs associated with the treatment of breast cancer-related lymphoedema? A systematic review. Support Care Cancer 28(2): 439-449, 2020. PMID: 31656987. DOI: 10.1007/s00520-019-05101-8
    OpenUrlCrossRefPubMed
    1. Co M,
    2. Lee A and
    3. Kwong A
    : Cutaneous angiosarcoma secondary to lymphoedema or radiation therapy - a systematic review. Clin Oncol (R Coll Radiol) 31(4): 225-231, 2019. PMID: 30738715. DOI: 10.1016/j.clon.2019.01.009
    OpenUrlCrossRefPubMed
    1. Visser J,
    2. van Geel M,
    3. Cornelissen AJM,
    4. van der Hulst RRWJ and
    5. Qiu SS
    : Breast cancer-related lymphedema and genetic predisposition: a systematic review of the literature. Lymphat Res Biol 17(3): 288-293, 2019. PMID: 30358483. DOI: 10.1089/lrb.2017.0083
    OpenUrlCrossRefPubMed
    1. Zomkowski K,
    2. Cruz de Souza B,
    3. Pinheiro da Silva F,
    4. Moreira GM,
    5. de Souza Cunha N and
    6. Sperandio FF
    : Physical symptoms and working performance in female breast cancer survivors: a systematic review. Disabil Rehabil 40(13): 1485-1493, 2018. PMID: 28325132. DOI: 10.1080/09638288.2017.1300950
    OpenUrlCrossRefPubMed
    1. Leysen L,
    2. Beckwée D,
    3. Nijs J,
    4. Pas R,
    5. Bilterys T,
    6. Vermeir S and
    7. Adriaenssens N
    : Risk factors of pain in breast cancer survivors: a systematic review and meta-analysis. Support Care Cancer 25(12): 3607-3643, 2017. PMID: 28799015. DOI: 10.1007/s00520-017-3824-3
    OpenUrlCrossRefPubMed
    1. Abbaci M,
    2. Conversano A,
    3. De Leeuw F,
    4. Laplace-Builhé C and
    5. Mazouni C
    : Near-infrared fluorescence imaging for the prevention and management of breast cancer-related lymphedema: A systematic review. Eur J Surg Oncol 45(10): 1778-1786, 2019. PMID: 31221460. DOI: 10.1016/j.ejso.2019.06.009
    OpenUrlCrossRefPubMed
    1. Sierla R,
    2. Dylke ES and
    3. Kilbreath S
    : A systematic review of the outcomes used to assess upper body lymphedema. Cancer Invest 36(8): 458-473, 2018. PMID: 30289283. DOI: 10.1080/07357907.2018.1517362
    OpenUrlCrossRefPubMed
    1. Burnier P,
    2. Niddam J,
    3. Bosc R,
    4. Hersant B and
    5. Meningaud JP
    : Indocyanine green applications in plastic surgery: A review of the literature. J Plast Reconstr Aesthet Surg 70(6): 814-827, 2017. PMID: 28292569. DOI: 10.1016/j.bjps.2017.01.020
    OpenUrlCrossRefPubMed
    1. Liu L,
    2. Yang Y,
    3. Guo Q,
    4. Ren B,
    5. Peng Q,
    6. Zou L,
    7. Zhu Y and
    8. Tian Y
    : Comparing hypofractionated to conventional fractionated radiotherapy in postmastectomy breast cancer: a meta-analysis and systematic review. Radiat Oncol 15(1): 17, 2020. PMID: 31952507. DOI: 10.1186/s13014-020-1463-1
    OpenUrlCrossRefPubMed
    1. Kanda MH,
    2. da Costa Vieira RA,
    3. Lima JPSN,
    4. Paiva CE and
    5. de Araujo RLC
    : Late locoregional complications associated with adjuvant radiotherapy in the treatment of breast cancer: Systematic review and meta-analysis. J Surg Oncol 121(5): 766-776, 2020. PMID: 31879978. DOI: 10.1002/jso.25820
    OpenUrlCrossRefPubMed
    1. Shaitelman SF,
    2. Chiang YJ,
    3. Griffin KD,
    4. DeSnyder SM,
    5. Smith BD,
    6. Schaverien MV,
    7. Woodward WA and
    8. Cormier JN
    : Radiation therapy targets and the risk of breast cancer-related lymphedema: a systematic review and network meta-analysis. Breast Cancer Res Treat 162(2): 201-215, 2017. PMID: 28012086. DOI: 10.1007/s10549-016-4089-0
    OpenUrlCrossRefPubMed
    1. Hugenholtz-Wamsteker W,
    2. Robbeson C,
    3. Nijs J,
    4. Hoelen W and
    5. Meeus M
    : The effect of docetaxel on developing oedema in patients with breast cancer: a systematic review. Eur J Cancer Care (Engl) 25(2): 269-279, 2016. PMID: 25348689. DOI: 10.1111/ecc.12261
    OpenUrlCrossRefPubMed
    1. Demiri E,
    2. Dionyssiou D,
    3. Tsimponis A,
    4. Goula OC,
    5. Mιlothridis P,
    6. Pavlidis L,
    7. Spyropoulou GA and
    8. Foroglou P
    : Donor-site lymphedema following lymph node transfer for breast cancer-related lymphedema: a systematic review of the literature. Lymphat Res Biol 16(1): 2-8, 2018. PMID: 29087763. DOI: 10.1089/lrb.2017.0043
    OpenUrlCrossRefPubMed
    1. Parks RM and
    2. Cheung KL
    : Axillary reverse mapping in N0 patients requiring sentinel lymph node biopsy - A systematic review of the literature and necessity of a randomised study. Breast 33: 57-70, 2017. PMID: 28282588. DOI: 10.1016/j.breast.2017.02.019
    OpenUrlCrossRefPubMed
    1. Bromham N,
    2. Schmidt-Hansen M,
    3. Astin M,
    4. Hasler E and
    5. Reed MW
    : Axillary treatment for operable primary breast cancer. Cochrane Database Syst Rev 1: CD004561, 2017. PMID: 28052186. DOI: 10.1002/14651858.CD004561.pub3
    OpenUrlCrossRefPubMed
    1. Gebruers N and
    2. Tjalma WA
    : Clinical feasibility of Axillary Reverse Mapping and its influence on breast cancer related lymphedema: a systematic review. Eur J Obstet Gynecol Reprod Biol 200: 117-122, 2016. PMID: 27019287. DOI: 10.1016/j.ejogrb.2016.03.014
    OpenUrlCrossRefPubMed
    1. Han C,
    2. Yang B,
    3. Zuo WS,
    4. Zheng G,
    5. Yang L and
    6. Zheng MZ
    : The feasibility and oncological safety of axillary reverse mapping in patients with breast cancer: a systematic review and meta-analysis of prospective studies. PLoS One 11(2): e0150285, 2016. PMID: 26919589. DOI: 10.1371/journal.pone.0150285
    OpenUrlCrossRefPubMed
    1. Paton M,
    2. Kovar A and
    3. Iorio ML
    : An evaluation of safety and patient outcomes for hand surgery following prior breast cancer treatment: Establishing new recommendations in lymphedema. Plast Reconstr Surg 145(2): 459-467, 2020. PMID: 31985641. DOI: 10.1097/PRS.0000000000006438
    OpenUrlCrossRefPubMed
    1. Co M,
    2. Ng J and
    3. Kwong A
    : Air travel safety in postoperative breast cancer patients: A systematic review. Clin Breast Cancer 18(5): e813-e817, 2018. PMID: 29859745. DOI: 10.1016/j.clbc.2018.05.003
    OpenUrlCrossRefPubMed
    1. Co M,
    2. Ng J and
    3. Kwong A
    : Air travel and postoperative lymphedema-a systematic review. Clin Breast Cancer 18(1): e151-e155, 2018. PMID: 29157874. DOI: 10.1016/j.clbc.2017.10.011
    OpenUrlCrossRefPubMed
    1. Shallwani SM,
    2. King J,
    3. Thomas R,
    4. Thevenot O,
    5. De Angelis G,
    6. Aburub AS and
    7. Brosseau L
    : Methodological quality of clinical practice guidelines with physical activity recommendations for people diagnosed with cancer: A systematic critical appraisal using the AGREE II tool. PLoS One 14(4): e0214846, 2019. PMID: 30969981. DOI: 10.1371/journal.pone.0214846
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Anticancer Research: 41 (7)
Anticancer Research
Vol. 41, Issue 7
July 2021
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Integrated Treatment of Breast Cancer-related Lymphedema: A Descriptive Review of the State of the Art
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
3 + 17 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Integrated Treatment of Breast Cancer-related Lymphedema: A Descriptive Review of the State of the Art
PAOLO MARCHICA, SALVATORE D’ARPA, STEFANO MAGNO, CRISTINA ROSSI, LUANA FORCINA, VITA CAPIZZI, SEBASTIANO OIENI, CARMELA AMATO, DARIO PIAZZA, VITTORIO GEBBIA
Anticancer Research Jul 2021, 41 (7) 3233-3246; DOI: 10.21873/anticanres.15109

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Integrated Treatment of Breast Cancer-related Lymphedema: A Descriptive Review of the State of the Art
PAOLO MARCHICA, SALVATORE D’ARPA, STEFANO MAGNO, CRISTINA ROSSI, LUANA FORCINA, VITA CAPIZZI, SEBASTIANO OIENI, CARMELA AMATO, DARIO PIAZZA, VITTORIO GEBBIA
Anticancer Research Jul 2021, 41 (7) 3233-3246; DOI: 10.21873/anticanres.15109
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Limitations
    • Conclusion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Cytokine-based Cancer Immunotherapy: Challenges and Opportunities for IL-10
  • Proteolytic Enzyme Therapy in Complementary Oncology: A Systematic Review
  • Multimodal Treatment of Primary Advanced Ovarian Cancer
Show more Reviews

Similar Articles

Keywords

  • Breast cancer-related lymphedema
  • physical therapy
  • physical exercise
  • surgery
  • photo-biomodulation therapy
  • complementary medicine
  • review
Anticancer Research

© 2023 Anticancer Research

Powered by HighWire